RESUMEN
Background: Drug induced inhibition of acid secretion has been associated to small intestinal bacterial overgrowth (SIBO). Smoking is followed by an increase of exhaled and orocecal transit time (OCTT). Aim: To investigate if the use of proton pump inhibitiors (PPI) and smoking can modifie the incidence of SIBO in patients with functional gastrointestinal disease. Patients and Methods: Questionnaires performed before a study for SIBO in patients with functional gastrointestinal disorders were analyzed. The use PPI and the smoking habit were recorded. The presence of SIBO and the OCTT was determined by means of the lactulose hydrogen breath test. Results: 437 patients, mean age 45 years (range: 14-93), 337 (77 percent) female, entered in the study SIBO was present in 356 patients, and 81 patients had normal H2 breath test. Both groups had a similar distribution of gender and age. The percentage of SIBO was no different in patients using PPI or presenting smoking habit Conclusions: Use of PPI and smoking habit are not risk factors for the development of SIBO in patients with functional disorders.
Los fármacos que inhiben la secreción gástrica favorecen el sobrecrecimiento bacteriano intestinal (SBI), mientras que el habito de fumar puede aumentar los niveles de H2 espirado y el tiempo de transito orocecal (TTOC). Objetivo: Investigar si el uso de inhibidores de la bomba de protones (IBP) y el habito de fumar modifican la incidencia de SBI en pacientes con trastornos digestivos funcionales. Pacientes y Métodos: Se analizaron encuestas de pacientes con patología digestiva funcional previas a un estudio de SBI Se consignaron el uso de IBP Y el hábito tabáquico en los 6 meses que precedieron al examen. La presencia de SBI y el tiempo de transito orocecal (TTOC) se determinaron con el test de hidrógeno en aire espirado con lactulosa. Resultados: 437 pacientes, con edad x 45 años (rango: 14-93),337 (77 por ciento) mujeres. Con SBI 356 pacientes, sin SBI 81 pacientes. Ambos grupos fueron comparables en cuanto a distribución por sexo y edad. El porcentaje de pacientes con SBI no fue diferente en pacientes con antecedente de uso de IBP o con hábito tabaquito. Conclusiones: El antecedente del uso de IBP y el tabaquismo no constituyen un factor de riesgo para SBI en pacientes con patología digestiva funcional.
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano de 80 o más Años , Antiulcerosos/farmacología , Bacterias/crecimiento & desarrollo , Bacterias , Nicotina/farmacología , Bombas de Protones/antagonistas & inhibidores , Chile/epidemiología , Factores de Tiempo , Hidrógeno/análisis , Intestinos , Lactulosa/administración & dosificación , Omeprazol/farmacología , Pruebas Respiratorias , Tránsito Gastrointestinal/fisiologíaRESUMEN
Medication of gastrointestinal disorders in the pregnancy, as well as of other pathological conditions, represent an important challenge for gastroenterologist and obstetrician. Several new medications has been developed in the last year and an adequate knowledge about the risks and benefits of different drugs involved in the treatment of these patients is very important. Classification of the drugs used in gastrointestinal diseases as well the available evidence of the effects these drugs during pregnancy is analyzed.
El tratamiento de las enfermedades gastrointestinales en el embarazo, así como otras condiciones patológicas, representa un importante desafió para los gastroenterólogos y obstetras. Nuevos medicamentos han sido desarrollados en el último tiempo y un adecuado conocimiento sobre los riesgos y beneficios de las diferentes drogas involucradas en el tratamiento de estas pacientes es muy importante. La clasificación de las drogas usadas en las enfermedades gastrointestinales, así como la evidencia disponible de los efectos de estos medicamentos durante el embarazo es analizada.
Asunto(s)
Humanos , Antagonistas de los Receptores H2 de la Histamina , Inmunosupresores/uso terapéutico , Antieméticos/uso terapéutico , Complicaciones del Embarazo/tratamiento farmacológico , Enfermedades Gastrointestinales/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , Antibacterianos/efectos adversos , Antidiarreicos/uso terapéutico , Bombas de Protones/antagonistas & inhibidores , Catárticos/uso terapéutico , Complicaciones del Embarazo/inducido químicamente , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Síndrome del Colon Irritable/tratamiento farmacológico , Úlcera Péptica/tratamiento farmacológicoRESUMEN
The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15 percent) and AUC0-10 h (30 vs 10 percent) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals.
Asunto(s)
Humanos , Adulto , Antibacterianos/farmacocinética , Antiulcerosos/administración & dosificación , Claritromicina/farmacocinética , Helicobacter pylori , Infecciones por Helicobacter/tratamiento farmacológico , /administración & dosificación , Antibacterianos/uso terapéutico , Disponibilidad Biológica , Estudios de Casos y Controles , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Claritromicina/uso terapéutico , Sinergismo Farmacológico , Bombas de Protones/antagonistas & inhibidores , Factores de TiempoAsunto(s)
2-Piridinilmetilsulfinilbencimidazoles/uso terapéutico , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiulcerosos/uso terapéutico , Quimioterapia Combinada , Femenino , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Omeprazol/uso terapéutico , Estudios Prospectivos , Bombas de Protones/antagonistas & inhibidores , Gastropatías/tratamiento farmacológico , Tinidazol/uso terapéutico , Resultado del TratamientoRESUMEN
OBJETIVO: Rever a literatura sobre tratamento da doença do refluxo gastroesofágico (DRGE) com ênfase nos aspectos farmacológicos. Identificar particularidades do tratamento farmacológico nas manifestações esofágicas e extra-esofágicas da doença. FONTES DE DADOS: Busca eletrônica na base de dados PubMed/MEDLINE e Cochrane Collaboration. Procurou-se identificar estudos controlados e randomizados publicados a partir de 2000, bem como revisões que representassem consensos e diretrizes publicados nos últimos 10 anos. SíNTESE DOS DADOS: Nenhuma das drogas atualmente usadas no tratamento da DRGE altera comprovadamente o mecanismo principal da doença, ou seja, os relaxamentos transitórios do esfíncter esofágico inferior. O tratamento farmacológico da DRGE com sintomas ou com lesões esofágicas é baseado na inibição da secreção ácida, em particular pelos inibidores da bomba de prótons (IBP). Nas situações em que a hiper-reatividade das vias aéreas inferiores coexiste com sintomas esofágicos da DRGE, a inibição da secreção ácida deve trazer benefícios na condução da doença respiratória se houver uma relação causal; contudo, essa situação não é comum. Quando não coexistem sintomas esofágicos, a pHmetria esofágica de 24 h deve ser realizada previamente ao tratamento farmacológico da DRGE. A melhora dos sintomas respiratórios pode ser tardia em relação aos sintomas esofágicos. A DRGE freqüentemente recorre, e o tratamento farmacológico deve ser repetido ou mantido indefinidamente, conforme a apresentação clínica da doença. CONCLUSÃO: As condutas propostas para o tratamento farmacológico da DRGE na criança são oriundas principalmente de estudos de séries de casos ou de estudos em adultos. Existem poucos estudos controlados e randomizados em crianças. A realização de um número maior desses estudos poderá reafirmar ou introduzir novos aspectos nas condutas propostas.
OBJECTIVE: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects. To identify particularities of pharmacological treatment of esophageal and extraesophageal manifestations of the disease. SOURCES: Electronic search of the PubMed/MEDLINE and Cochrane Collaboration databases. Controlled and randomized studies published since 2000 and reviews representing consensus positions and directives published within the last 10 years were identified. SUMMARY OF THE FINDINGS: The drugs currently available for the treatment of GERD do not act in the primary mechanism of the disease, i.e., transitory relaxation of the lower esophageal sphincter. Pharmacological treatment of GERD with symptoms or with esophageal injury is based on the suppression of acid secretion, particularly with proton pump inhibitors. When the hyperreactivity of the lower airways coexists with esophageal GERD symptoms, suppression of acid secretions should be of benefit in managing the respiratory disease in the presence of a causal relationship; however, this is not usual. When esophageal symptoms are not present, esophageal 24-hour pH study should be carried out prior to starting pharmacological treatment for GERD. Improvement of respiratory symptoms may be delayed with relation to esophageal symptoms. It is common for GERD to recur and pharmacological treatment should be repeated or continued indefinitely, depending on clinical presentation of the disease. CONCLUSIONS: The strategies that have been proposed for the pharmacological treatment of GERD in children are primarily based on studies of case series or on studies with adults. There have been very few controlled and randomized studies in children. Undertaking a greater number of these studies might reinforce existing aspects or establish new aspects of management.
Asunto(s)
Humanos , Lactante , Preescolar , Niño , Adolescente , Adulto , Antiulcerosos/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Omeprazol/uso terapéutico , /uso terapéutico , Dolor Abdominal/patología , Esófago de Barrett/tratamiento farmacológico , Esófago de Barrett/etiología , Estenosis Esofágica/tratamiento farmacológico , Estenosis Esofágica/etiología , Esofagitis/tratamiento farmacológico , Esofagitis/etiología , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/diagnóstico , Concentración de Iones de Hidrógeno , /farmacología , Estilo de Vida , Bombas de Protones/antagonistas & inhibidores , Bombas de Protones/farmacología , Síndrome , Vómitos/patologíaRESUMEN
PURPOSE: To evaluate models of gastric material collection from Wistar rats with and without using proton pump inhibitors(PPIs). METHODS: Twenty-four rats underwent intraperitoneal omeprazol treatment, and other 12 received similar treatment with 0.9 percent saline. All animals underwent collection of gastric material samples, after stomach removal, by either biopsies, or aspirates, or swabs. Samples were bacteriologically processed in order to identify species and strains. Values are described as natural logarithm of colony former units per mL [Ln(CFU/mL)]. Kruskal-Wallis and Mann-Whitney non-parametric tests were used, and p<0.05 was set as statistically significant. RESULTS: Significant difference was not seen for Ln (UFC/mL) values among the three methods of collection irrespective of using or not omeprazol. Also, significant difference was not seen in Ln (UFC/mL) values when comparing a method with each others, either using omeprazol or placebo. A significant increase of bacteria strains occurred when PPI was used, and this was seen on the three ways of collection, mainly in biopsy and swab. CONCLUSION: No difference occurred among the three methods of collecting bacteria samples from stomachs of rats, either when using placebo or omeprazol. A remarkable change is seen on animals bacterial microflora when PPIs are used, and bacteria are better identified when swab and biopsy are used.
OBJETIVO: Avaliar modelos de coleta de material gástrico de ratos da linhagem Wistar, com e sem o uso de inibidores de bomba de próton (IBPs). MÉTODOS: 24 ratos foram submetidos a tratamento com omeprazol intraperitoneal e 12 outros ratos receberam tratamento semelhante com solução salina a 0,9 por cento. Os animais foram submetidos a coleta de amostras de material gástrico, após retirada do estômago, utilizando-se de biópsias, aspirados ou swabs. Os materiais obtidos foram processados bacteriologicamente para identificação de espécimes quanto ao gênero. Os valores são descritos em logaritmo natural das unidades formadoras de colônias por mL [Ln(UFC/mL)]. Utilizou-se os testes não-paramétricos de Kruskal-Wallis e Mann-Whitney, considerando-se p<0,05 como estatisticamente significativo. RESULTADOS: Não se observou diferença significativa da quantidade de Ln(UFC/mL) entre os três métodos de coleta, independente do uso de omeprazol. Também não se observou diferença significativa de Ln(UFC/mL) ao comparar-se os métodos individualmente entre si nas condições de uso de omeprazol ou placebo. Houve aumento significativo da variedade de gêneros de bactérias com o uso de IBP, nos 3 métodos de coleta, sendo isto mais perceptível na biópsia e swab. CONCLUSÃO: Não houve diferença entre os três métodos de coleta de amostras bacterianas de estômago de ratos, tanto em uso de placebo quanto em uso de omeprazol. Nota-se uma mudança evidente da microflora bacteriana nos animais em uso de IBPs, sendo melhor identificado pelos métodos de swab e biópsia.
Asunto(s)
Animales , Ratas , Mucosa Gástrica/microbiología , Infecciones por Helicobacter/microbiología , Helicobacter pylori/aislamiento & purificación , Bombas de Protones/antagonistas & inhibidores , Manejo de Especímenes/métodos , Aclorhidria/inducido químicamente , Aclorhidria/microbiología , Antiulcerosos/efectos adversos , Biopsia , Biopsia con Aguja , Recuento de Colonia Microbiana , Modelos Animales de Enfermedad , Determinación de la Acidez Gástrica , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/fisiopatología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Omeprazol/efectos adversos , Bombas de Protones/uso terapéutico , Ratas Wistar , Estadísticas no Paramétricas , Manejo de Especímenes/normasAsunto(s)
Alginatos/administración & dosificación , Antiácidos/administración & dosificación , Interacciones Farmacológicas , Quimioterapia Combinada , Reflujo Gastroesofágico/tratamiento farmacológico , Humanos , Omeprazol/administración & dosificación , Bombas de Protones/antagonistas & inhibidoresRESUMEN
BACKGROUND & OBJECTIVE: Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux. There is limited pharmacokinetic information regarding possible drug interaction between these two types of products, although these may be frequently co-prescribed to improve symptom control in GORD patients. This study was designed to determine whether the administration of a 10 per cent w/v liquid alginate suspension affected the pharmacokinetic profile of omeprazole. METHODS: This was a randomized, two-treatment, two-sequence, two-period crossover study in 26 volunteers. Each treatment was dosed for 3 consecutive days with a washout period of 7 days between dosing periods. Blood samples for pharmacokinetic analysis were taken over the 24 h period following the final dose of omeprazole. RESULTS: Geometric means and ratios were as follows: C(max) was 555 for omeprazole/alginate and 558 for omeprazole alone (ratio 99.55%, 90% confidence interval 82.75-119.75%; AUC(0-t) was 2050 for omeprazole/alginate and 2094 for omeprazole alone (ratio 97.90%, 90% confidence interval 87.83-109.12%); AUC(0-a) was 2247 for omeprazole/alginate and 2231 for omeprazole alone (ratio 100.74%, 90% confidence interval 90.05-112.70%). Mean values for T(max), K(el) and T(1/2) were also similar for the two treatment regimens. INTERPRETATION & CONCLUSION: As the 90 per cent confidence intervals for the geometric mean ratios for C(max), AUC(0-t), and AUC(0-alpha) are all contained within the bioequivalence interval of 80-125 per cent, it can be concluded that the administration of this liquid alginate suspension does not affect the pharmacokinetic profile of omeprazole.
Asunto(s)
Adolescente , Adulto , Alginatos/administración & dosificación , Antiácidos/administración & dosificación , Disponibilidad Biológica , Estudios Cruzados , Interacciones Farmacológicas , Quimioterapia Combinada , Reflujo Gastroesofágico/tratamiento farmacológico , Humanos , Masculino , Omeprazol/administración & dosificación , Bombas de Protones/antagonistas & inhibidoresRESUMEN
La enfermedad por reflujo gastroesofágico puede generarsíntomas respiratorios. Éstos se desencadenan cuandoel contenido esofágico refluye a la vía aérea, generandouna microaspiracion; o a través de un reflejo vago-vagal. Los síntomas respiratorios pueden ser vagos ycoexistir con la enfermedad por reflujo, sin una verdaderarelación causa-efecto. Para tratar estos pacientes,es fundamental realizar un diagnóstico preciso que asocielas dos entidades. El algoritmo debe incluir estudiosque detecten reflujo gastroesofágico, microaspiración y,de corresponder, lesión laríngea. A continuación, se debeaplicar la terapéutica más efectiva. El tratamientomédico posee menor tasa de éxito si lo comparamos conla obtenida en pacientes con síntomas típicos. Esto puededeberse a que episodios de reflujo no-ácido son losgeneradores de síntomas, a la existencia de un dañoirreversible en la vía aérea o a dosis insuficientes demedicación para neutralizar el ácido. La fundoplicaturaes un tratamiento efectivo que frena todo tipo dereflujo patológico (ácido y no-ácido). Este artículo describela utilidad de los tests diagnósticos y menciona losresultados obtenidos con las diversas formas de tratamiento.Adicionalmente, comenta acerca de la potencialaplicación de la impedancia esófago-faringea enesta población.
Gastroesophageal reflux disease can cause respiratory symptoms. These symptoms are triggered by reflux events that reach the pharynx, causing microaspiration or through vagal reflex. Respiratory symptoms can be vague and coexist with gastroesophageal reflux disease, without a real link between the two entities. To effectively treat these patients, it is important tofind an association between the two diseases. Work up should include the diagnosis of reflux disease, the diagnosis of pharyngeal reflux events -microaspiration - and, if possible, of laryngeal injury. Once the diagnosis has been established, an effective therapy must be offered to the patient. In these patients, medical treatment is less effective when compared to the results in the population with typical symptoms. This may be due to the fact that non-acid reflux episodes are causing the respiratory symptoms or as a result of an irreversible damage generated in the airway. Antireflux surgery is an effective therapy that reduces both acid and non-acid reflux events. This article describes the different diagnostic tests as well as the results obtained with surgical treatment in this population. Additionally, it describes potential applications of esophageal and pharyngeal impedance monitoring in these patients.
Asunto(s)
Humanos , Bombas de Protones/antagonistas & inhibidores , Reflujo Gastroesofágico/complicaciones , Trastornos Respiratorios/etiología , Concentración de Iones de Hidrógeno , Faringe/fisiopatología , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/terapia , Pruebas de Impedancia Acústica , Trastornos Respiratorios/diagnóstico , Trastornos Respiratorios/terapiaRESUMEN
INTRODUÇÃO: A Doença do Refluxo Gastroesofágico (DRGE) é a doença digestiva mais prevalente da atualidade e, recentemente, tem sido implicada em uma gama de alterações do seguimento laringofaríngeo (RLF). No entanto, pouco se sabe dos mecanismos fisiopatológicos destas manifestações supraesofágicas da DRGE. Os achados clínicos contraditórios e recentes pesquisas sugerem haver deficiências na capacidade de defesa deste seguimento. Uma das principais responsáveis pela homeostase da mucosa oral e do trato digestivo é a saliva com seu conteúdo orgânico e inorgânico. Tanto alterações do pH quanto do volume salivar já foram correlacionados com os sintomas e sinais sugestivos da DRGE e RLF. Estudo recente de nossa autoria demonstra diminuição estatisticamente significante do pH salivar de indivíduos com RLF quando comparado a controles sem a doença. Outro estudo constatou correlação entre a redução do volume X pH da saliva em indivíduos com DRGE, estando esta redução diretamente relacionada aos níveis de pH esofágico constatados durante pH-metria esofágica de 24 horas. OBJETIVOS: Avaliar como se comportam o pH e volume da saliva em um mesmo indivíduo com DRGE e RLF antes e após o tratamento clínico. MATERIAL E MÉTODO: Vinte e três pacientes com RLF tiveram o pH e volume da saliva total testados antes e após receberem tratamento com droga bloqueadora de bomba de prótons durante 12 semanas. RESULTADOS: Houve uma diferença estatisticamente significante (p<0,001) entre o pH da saliva antes e após o tratamento, estando este maior após o controle clínico da doença. O volume de saliva no paciente tratado foi significativamente maior do que no paciente pré-tratamento (p=0.009). DISCUSSÃO: Os achados sugerem que o pH salivar é influenciado pela presença de refluxo gastroduodenal à região laringofaríngea. Caso estudos futuros com populações maiores realmente comprovem esta correlação, poderemos cogitar a possibilidade de usar a mensuração do pH salivar, que é feita de forma rápida e não invasiva, como um meio de diagnosticar e avaliar o comportamento e controle do Refluxo Laringofaríngeo.
INTRODUCTION: Gastroesophageal Reflux Disease (GERD) is the most prevalent digestive disease of the modern society and has been associated with abnormalities in the larynx and pharynx (LPR). Nonetheless, little is known about the mechanisms involved in this atypical form of the disease. Contradictory clinical data suggest a defense deficit at this segment. Saliva with its organic and inorganic components is responsible for the homeostasis of the oral mucosa and the digestive tract. Salivary pH and volume abnormalities have been linked to laryngopharyngeal symptoms of GERD and LPR. In a recent study we demonstrated significant salivary pH reduction in patients with LPR. Another study found correlation between reduced salivary pH and volume directly related to esophageal pH-metry results. AIM: To evaluate salivary pH and volume before and after clinical treatment of LPR. MATERIAL AND METHOD: Twenty-three adults with LPR had total fasting saliva tested before and after a 12-week course of oral proton pump inhibitor. RESULTS: A statistically significant difference was found in salivary pH before and after treatment with increase of pH values after control of the disease (p<0.001). Salivary volumes of treated patients were also significantly higher than in pre-treated patients (p=0.009). DISCUSSION: These findings suggest that salivary pH and volume are influenced by the presence of gastroesophageal contents and that salivary pH monitoring can potentially become a cost-effective method for diagnosing and controlling LPR.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Bombas de Protones/antagonistas & inhibidores , Faringitis/diagnóstico , Laringitis/diagnóstico , Omeprazol/uso terapéutico , Saliva/química , Bombas de Protones/farmacología , Enfermedad Crónica , Concentración de Iones de Hidrógeno/efectos de los fármacos , Faringitis/tratamiento farmacológico , Faringitis/etiología , Laringitis/tratamiento farmacológico , Laringitis/etiología , Manometría , Monitoreo Fisiológico , Omeprazol/farmacología , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/tratamiento farmacológico , Saliva/efectos de los fármacos , SalivaRESUMEN
We describe a 58-year-old woman who was incidentally found to have gastric and colonic polyposis, hypoalbuminemia, cutaneous hyperpigmentation and onychodystrophy (Cronkhite-Canada syndrome). Histology of polyps from the stomach showed features of juvenile or retention type (hamartomatous) polyps with Helicobacter pylori (H. pylori) infection. The large pedunculated colonic polyps showed hamartomatous polyps with adenomatous component and polypectomy was performed. After the treatment with H. pylori eradication and omeprazole, the gastric polyposis, hypoalbuminemia and anemia regressed, and endoscopic polypectomy of gastric polyps were performed. After the continuous use of omeprazole for 14 months, the patient showed complete resolution of clinical features of Cronkhite-Canada syndome. The experience of this case suggests that eradication of H. pylori and proton pump inhibitor treatment might be considered in patients with gastric polyposis combined with Cronkhite-Canada syndome.
Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Antiulcerosos/uso terapéutico , Pólipos del Colon/complicaciones , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Hiperpigmentación/patología , Uñas Malformadas/patología , Omeprazol/uso terapéutico , Pólipos/complicaciones , Bombas de Protones/antagonistas & inhibidores , Neoplasias Gástricas/complicaciones , SíndromeRESUMEN
BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H2-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy. METHODS: A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement. RESULTS: After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test. CONCLUSIONS: In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , 2-Piridinilmetilsulfinilbencimidazoles , Antiulcerosos/uso terapéutico , Bencimidazoles/uso terapéutico , Esofagitis Péptica/tratamiento farmacológico , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Omeprazol/análogos & derivados , Bombas de Protones/antagonistas & inhibidores , ATPasas de Translocación de Protón/uso terapéutico , Ranitidina/uso terapéuticoRESUMEN
The development and introduction into clinical practice of proton pump inhibitors (PPIs) have influenced the management of acid-peptic disorders dramatically. PPIs inhibit the gastric hydrogen/potassium adenosine triphosphatase selectively and irreversibly which is the final step in acid secretion. PPIs are currently the most effective form of therapy in acid-peptic diseases. All PPIs are potent, effective and generally safe, but little different in equivalent doses. PPIs undergo hepatic metabolism by cytochrome P450 (CYP) system. Polymorphism of CYP2C19 influences the pharmacokinetics and pharmacodynamics of PPIs. Doses and dosing schemes of PPIs based on CYP2C19 genotype status is expected to increase the efficacy in clinical outcome. The major indication of PPIs are acid-related diseases such as peptic ulcers and their complications, gastroesophageal reflux diseases, Zollinger-Ellison syndrome and eradication of Helicobacter pylori with antibiotics and dyspepsia. The potency and cost-effectiveness of PPIs have extended their clinical uses. However, their widespread and long-term use may limit the therapeutic benefit between efficacy and clinical problems such as acid rebound hypersecretion, enhanced oxyntic gastritis, problems with carcinoids in rodents and long-term concern for gastric cancer development. Further studies are needed to minimize the side effects and to maximize the therapeutic effects of PPIs.
Asunto(s)
Animales , Humanos , Antiulcerosos/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Úlcera Péptica/tratamiento farmacológico , Bombas de Protones/antagonistas & inhibidoresRESUMEN
During the last 15 years management of patients who need to take non-steroidal anti-inflammatory drugs [NSAIDs] has been revolutionised by the availability,for co-prescription of prostaglandin analogues such as misoprostol or proton pump inhibitors and by the emergence of selective inhibitors of the inducible cyclo-oxygenase [COX]-2 enzyme. This paper describes work mainly from the Division of Gastroenterology [now Wolfson Digestive Diseases Centre], that investigated numerous strategies in acute and/or explanatory studies before evaluating their effectiveness in large patient studies with endoscopy or clinical outcome as an endpoint. The data show, contrary to common pre-conception, that acute changes are highly predictive of patient outcomes. It seems likely that some strategies that were never evaluated in patient studies would be effective
Asunto(s)
Humanos , Antiinflamatorios no Esteroideos , Prostaglandina-Endoperóxido Sintasas , Prostaglandinas , Inhibidores de la Ciclooxigenasa 2 , Bombas de Protones/antagonistas & inhibidores , Donantes de Óxido Nítrico/antagonistas & inhibidores , Lipooxigenasa , Helicobacter pyloriRESUMEN
The aim of the study was to estimate the frequency and clinical spectrum of respiratory poblems in gastro esophageal disease and assess the response to high dose proton pump inhibitor [PPI]. This was a prospective study in which 382 patients were recruited in 2004 and 2005 who presented with heart burn or regurgitation and found to have esophagitis on endoscopy. Sixteen percent patients had respiratory symptoms with most common problem being chronic cough and asthma or asthma-like symptoms. Patients with hiatus hernia and higher body mass index had strong correlation with these symptoms. Fifty four percent of patients' symptoms improved on PPI. Maximum improvement was in the nocturnal symptoms Recognition and treatment of reflux can produce worthwhile improvement in respiratory illness. This response is sometime dramatic
Asunto(s)
Humanos , Reflujo Gastroesofágico , Bombas de Protones/antagonistas & inhibidores , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento , Hernia Hiatal , Asma , TosRESUMEN
Proton pump inhibitors (PPIs) are widely used in clinical practice from early 1990s for the treatment of acid- related diseases. PPIs are superior to histamine2-receptor antagonists or anticholinergic agents. These drugs have proven to be effective, safe and well-tolerated during the past two decades. This brief review presents the pharmacodynamics and pharmacokinetics of PPIs and presents clincal applications of the drugs in acid-related diseases.
Asunto(s)
Humanos , Ácido Gástrico/metabolismo , Fármacos Gastrointestinales/farmacocinética , Bombas de Protones/antagonistas & inhibidoresRESUMEN
BACKGROUND/AIMS: At present, triple therapy schemes are recommended by national and international consensus conferences for the treatment of Helicobacter pylori (H. pylori) infection. However, even with the most effective current treatment regimens, about 10-20% of patients fail to eradicate H. pylori, necessitating alternative strategy to eradicate H. pylori in primary treatment failure. Therefore, we performed this study to evaluate the efficacy of quadruple therapy and to compare 1 and 2-week quadruple regimen as a second-line therapy. METHODS: The hospital records of 155 patients who failed to the standard triple therapy (proton pump inhibitor, amoxicillin, clarithromycin) were reviewed retrospectively, and divided the 1 or 2 weeks OBMT regimen (omeprazole 20 mg bid, bismuth salt 120 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid). Presence of H. pylori infection and side-effects of the treatment regimen were assessed 4 weeks after the cessation of treatment. CONCLUSIONS: One hundred and eight male and 47 female (mean age, 52.2+/-15.4) patients were enrolled. The overall eradication rate of H. pylori with quadruple therapy was 83.9% and the eradication rate was similar between 1 and 2 weeks of OBMT regimen (76.8% in OBMT 1 week, 87.9% in OBMT 2 weeks, respectively p=0.110). CONCLUSIONS: Quadruple therapy is an effective salvage regimen for H. pylori eradication after the failure of standard triple therapy. One week quadruple therapy is not significantly different from 2-weeks regimen as the second-line option for H. pylori eradication.
Asunto(s)
Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antibacterianos/administración & dosificación , Antiulcerosos/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Bombas de Protones/antagonistas & inhibidoresRESUMEN
Por largo tiempo y hasta no hace muchos años, la úlcera gastroduodenal era una de las enfermedades digestivas más importantes por su frecuencia; sus complicaciones y su casi inevitable tendencia a la recurrencia. Actualmente esto ya no es así debido al descubrimiento de los bloqueadores de la secreción gástrica, que han desplazado los antiácidos de acción sólo sintomática y fugaz y finalmente debido al hallazgo del Helicobacter pylori y a la disponibilidad de un tratamiento antibiótico altamente eficaz.
Asunto(s)
Humanos , Helicobacter pylori , Úlcera Péptica/tratamiento farmacológico , Ácido Clorhídrico/efectos adversos , Ácido Gástrico , Antibacterianos/uso terapéutico , Antagonistas Colinérgicos/uso terapéutico , Bombas de Protones/antagonistas & inhibidores , Farmacorresistencia Bacteriana , Antagonistas de los Receptores H2 de la Histamina , Recurrencia , Terapéutica/tendencias , Úlcera Péptica/etiologíaRESUMEN
BACKGROUND/AIMS: Quadruple therapy can be considered as a first-line therapy in areas where the resistance rate to clarithromycin is high. Comparison study of triple therapy and quadruple therapy for Helicobacter pylori (H. pylori) eradication is still lacking in Korea despite the increasing prevalence of antibiotic resistance. This study was conducted to compare the efficacy of triple and quadruple therapy as a first-line treatment in H. pylori infected patients with peptic ulcer. METHODS: Consecutive 149 cases of peptic ulcer disease associated with H. pylori infection were randomized either to proton pump inhibitor (PPI, bid), amoxicillin (1,000 mg, bid), and clarithromycin (500 mg, bid) (PAC group) or to PPI (bid), bismuth subcitrate (300 mg, qid), metronidazole (500 mg, tid), and tetracycline (500 mg, qid) (PBMT group) eradication treatments for 7 days. Outcome of eradication therapy was assessed by 13C-urea breath test performed 4-6 weeks after eradication. RESULTS: Eradication rates in PAC and PBMT group were 78.7% (59/75) and 71.6% (53/74) by intention to treat analysis, respectively (p=0.424). By per protocol analysis, eradication rates of PAC and PBMT group were 85.5% (59/69) and 85.5% (53/62), respectively (p=1.012). Adverse reactions occurred in 5 (6.6%) and 7 (9.5%) patients in PAC and PBMT group, respectively (p=0.346). CONCLUSIONS: One week-quadruple therapy as a first-line treatment for H. pylori infection does not offer any advantage over PPI-based triple therapy in Korean patients.